Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Lage versus hoge dosis GC plus rituximab bij ANCA-vasculitis: resultaten na 2 jaar
jan 2024